Market Cap 69.96M
Revenue (ttm) 58.44M
Net Income (ttm) -34.28M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -58.66%
Debt to Equity Ratio 0.00
Volume 63,300
Avg Vol 136,794
Day's Range N/A - N/A
Shares Out 12.10M
Stochastic %K 80%
Beta 0.84
Analysts Strong Sell
Price Target $8.50

Company Profile

LENSAR, Inc., a commercial-stage medical device company, focuses on designing, developing, and marketing laser systems for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism in the United System, Europe, Asia, South Korea, and internationally. The company offers the LENSAR Laser System, which incorporates a range of proprietary technologies designed to assist the surgeon in obtaining visual outcomes by providing imaging, procedure planning, de...

Industry: Medical Devices
Sector: Healthcare
Phone: 888 536 7271
Address:
2800 Discovery Drive, Orlando, United States
MarketBeat
MarketBeat May. 8 at 8:03 PM
LENSAR Q1 Earnings Call Highlights $LNSR #LENSAR #instantalerts #NASDAQ:LNSR https://www.marketbeat.com/instant-alerts/lensar-q1-earnings-c
0 · Reply
ap20
ap20 May. 8 at 4:49 PM
$LNSR I think the corner turned.
1 · Reply
StocktwitsEarnings
StocktwitsEarnings May. 8 at 11:10 AM
$LNSR Q1 '26 Earnings Results & Recap • Reported GAAP EPS of $1.56 up 167.24% YoY • Reported revenue of $13.43M down -5.16% YoY
0 · Reply
Alidrisi
Alidrisi May. 2 at 4:19 AM
0 · Reply
ap20
ap20 Apr. 23 at 6:59 PM
$LNSR maybe a half double from here.. ‘Hope $5 the bottom..
0 · Reply
ap20
ap20 Apr. 14 at 5:07 PM
$LNSR Easy double from here..
0 · Reply
AdrianCartier
AdrianCartier Apr. 11 at 10:30 AM
$LNSR lets gooo 6-7$🚀
0 · Reply
AdrianCartier
AdrianCartier Apr. 11 at 10:29 AM
$LNSR 6-7$
0 · Reply
SwingTraderPro1
SwingTraderPro1 Apr. 10 at 7:57 PM
For $LNSR, procedure volume has been doing well, with a >21% jump y/y, now up to >23% share in the U.S. The problem is with system sales, which are lacking. Management blames international distributors for being hesitant because of the merger. Not sure I buy that.
0 · Reply
TradeMechanics_
TradeMechanics_ Mar. 31 at 2:33 PM
Today’s move in $LNSR feels like a mix of beta tailwinds and a hint of alpha starting to show. What stood out? Recurring revenue. That’s the piece the market actually rewards over time — more predictable, more defensible, more scalable. That’s a quiet but important signal. The bigger question: why couldn’t the machines keep building on that earlier momentum? Lantern Pharma is at a point where execution matters more than narrative. If management can reignite growth and operational consistency over the next few quarters, this could shift from “watchlist” to “story re-rating.” For now, it’s not about one day’s price action — it’s about whether this becomes sustained traction or just another chop phase.
0 · Reply
Latest News on LNSR
LENSAR Earnings Call Transcript: Q1 2026

May 8, 2026, 8:30 AM EDT - 5 days ago

LENSAR Earnings Call Transcript: Q1 2026


LENSAR® to Report First Quarter 2026 Results on May 8, 2026

Apr 30, 2026, 7:00 AM EDT - 13 days ago

LENSAR® to Report First Quarter 2026 Results on May 8, 2026


Lensar upgraded to Buy from Hold at Lake Street

2026-04-01T12:41:01.000Z - 6 weeks ago

Lensar upgraded to Buy from Hold at Lake Street


LENSAR Earnings Call Transcript: Q4 2025

Mar 31, 2026, 8:30 AM EDT - 6 weeks ago

LENSAR Earnings Call Transcript: Q4 2025


Lensar reports Q4 EPS (12c) vs. ($1.61) last year

2026-03-31T10:07:00.000Z - 6 weeks ago

Lensar reports Q4 EPS (12c) vs. ($1.61) last year


Lensar upgraded to Buy from Neutral at BTIG

2026-03-17T20:17:07.000Z - 2 months ago

Lensar upgraded to Buy from Neutral at BTIG

ALC


Alcon, Lensar agree to terminate merger agreement

2026-03-16T21:00:45.000Z - 2 months ago

Alcon, Lensar agree to terminate merger agreement

ALC


LENSAR trading resumes

2026-03-16T21:00:14.000Z - 2 months ago

LENSAR trading resumes


LENSAR trading halted, news pending

2026-03-16T20:25:10.000Z - 2 months ago

LENSAR trading halted, news pending


LENSAR® Provides Update on Pending Acquisition by Alcon

Feb 25, 2026, 5:00 PM EST - 2 months ago

LENSAR® Provides Update on Pending Acquisition by Alcon


Lensar reports Q3 EPS (31c) vs. (13c) last year

2025-11-06T12:12:10.000Z - 6 months ago

Lensar reports Q3 EPS (31c) vs. (13c) last year


Lensar reports Q2 EPS (15c) vs (79c) last year

2025-08-07T11:43:09.000Z - 9 months ago

Lensar reports Q2 EPS (15c) vs (79c) last year


Lensar reports Q1 EPS ($2.32) vs. (19c) last year

2025-05-08T12:11:07.000Z - 1 year ago

Lensar reports Q1 EPS ($2.32) vs. (19c) last year


Lensar downgraded to Hold from Buy at Lake Street

2025-03-25T19:32:55.000Z - 1 year ago

Lensar downgraded to Hold from Buy at Lake Street


Lensar downgraded to Neutral from Buy at BTIG

2025-03-25T19:23:18.000Z - 1 year ago

Lensar downgraded to Neutral from Buy at BTIG


Alcon to acquire Lensar for $430M

2025-03-24T12:12:05.000Z - 1 year ago

Alcon to acquire Lensar for $430M

ALC


Alcon to acquire Lensar for $14.00 per share in cash

2025-03-24T12:10:56.000Z - 1 year ago

Alcon to acquire Lensar for $14.00 per share in cash

ALC


Lensar price target raised to $16 from $12 at Lake Street

2025-02-28T13:50:46.000Z - 1 year ago

Lensar price target raised to $16 from $12 at Lake Street


LENSAR Earnings Call Transcript: Q4 2024

Feb 27, 2025, 8:30 AM EST - 1 year ago

LENSAR Earnings Call Transcript: Q4 2024


LENSAR Earnings Call Transcript: Q3 2024

Nov 7, 2024, 8:30 AM EST - 1 year ago

LENSAR Earnings Call Transcript: Q3 2024


LENSAR to Participate in Two Upcoming Investor Conferences

Sep 4, 2024, 8:00 AM EDT - 1 year ago

LENSAR to Participate in Two Upcoming Investor Conferences


LENSAR Earnings Call Transcript: Q2 2024

Aug 8, 2024, 8:30 AM EDT - 1 year ago

LENSAR Earnings Call Transcript: Q2 2024


LENSAR Earnings Call Transcript: Q1 2024

May 9, 2024, 8:30 AM EDT - 2 years ago

LENSAR Earnings Call Transcript: Q1 2024


LENSAR Earnings Call Transcript: Q4 2023

Mar 4, 2024, 8:30 AM EST - 2 years ago

LENSAR Earnings Call Transcript: Q4 2023


LENSAR Earnings Call Transcript: Q3 2023

Nov 9, 2023, 8:30 AM EST - 2 years ago

LENSAR Earnings Call Transcript: Q3 2023


LENSAR Earnings Call Transcript: Q2 2023

Aug 9, 2023, 8:30 AM EDT - 3 years ago

LENSAR Earnings Call Transcript: Q2 2023


LENSAR Earnings Call Transcript: Q1 2023

May 15, 2023, 8:30 AM EDT - 3 years ago

LENSAR Earnings Call Transcript: Q1 2023


LENSAR Earnings Call Transcript: Q4 2022

Mar 16, 2023, 8:30 AM EDT - 3 years ago

LENSAR Earnings Call Transcript: Q4 2022


LENSAR to Present at Two Upcoming Investor Conferences

Nov 22, 2022, 8:00 AM EST - 3 years ago

LENSAR to Present at Two Upcoming Investor Conferences


LENSAR Earnings Call Transcript: Q3 2022

Nov 9, 2022, 8:30 AM EST - 3 years ago

LENSAR Earnings Call Transcript: Q3 2022


LENSAR Earnings Call Transcript: Q2 2022

Aug 8, 2022, 8:30 AM EDT - 4 years ago

LENSAR Earnings Call Transcript: Q2 2022


MarketBeat
MarketBeat May. 8 at 8:03 PM
LENSAR Q1 Earnings Call Highlights $LNSR #LENSAR #instantalerts #NASDAQ:LNSR https://www.marketbeat.com/instant-alerts/lensar-q1-earnings-c
0 · Reply
ap20
ap20 May. 8 at 4:49 PM
$LNSR I think the corner turned.
1 · Reply
StocktwitsEarnings
StocktwitsEarnings May. 8 at 11:10 AM
$LNSR Q1 '26 Earnings Results & Recap • Reported GAAP EPS of $1.56 up 167.24% YoY • Reported revenue of $13.43M down -5.16% YoY
0 · Reply
Alidrisi
Alidrisi May. 2 at 4:19 AM
0 · Reply
ap20
ap20 Apr. 23 at 6:59 PM
$LNSR maybe a half double from here.. ‘Hope $5 the bottom..
0 · Reply
ap20
ap20 Apr. 14 at 5:07 PM
$LNSR Easy double from here..
0 · Reply
AdrianCartier
AdrianCartier Apr. 11 at 10:30 AM
$LNSR lets gooo 6-7$🚀
0 · Reply
AdrianCartier
AdrianCartier Apr. 11 at 10:29 AM
$LNSR 6-7$
0 · Reply
SwingTraderPro1
SwingTraderPro1 Apr. 10 at 7:57 PM
For $LNSR, procedure volume has been doing well, with a >21% jump y/y, now up to >23% share in the U.S. The problem is with system sales, which are lacking. Management blames international distributors for being hesitant because of the merger. Not sure I buy that.
0 · Reply
TradeMechanics_
TradeMechanics_ Mar. 31 at 2:33 PM
Today’s move in $LNSR feels like a mix of beta tailwinds and a hint of alpha starting to show. What stood out? Recurring revenue. That’s the piece the market actually rewards over time — more predictable, more defensible, more scalable. That’s a quiet but important signal. The bigger question: why couldn’t the machines keep building on that earlier momentum? Lantern Pharma is at a point where execution matters more than narrative. If management can reignite growth and operational consistency over the next few quarters, this could shift from “watchlist” to “story re-rating.” For now, it’s not about one day’s price action — it’s about whether this becomes sustained traction or just another chop phase.
0 · Reply
ap20
ap20 Mar. 31 at 11:47 AM
$LNSR Second best sales revenue ever. Highest procedure volume ever. Things are still moving. Was $16 on 4q earnings day last year.. Risk reward at $6 pretty dang good. Long.
0 · Reply
DonCorleone77
DonCorleone77 Mar. 31 at 10:35 AM
$LNSR Lensar reports Q4 EPS (12c) vs. ($1.61) last year Reports Q4 revenue $16.03M vs. $16.73M last year. "While the recent transaction-related news was unexpected, we have quickly pivoted and are moving forward independently with a renewed commitment to advancing robotic laser cataract surgery through our industry-leading ALLY Robotic Laser Cataract System. Our objective is not only to expand our share of the laser-assisted cataract surgery market, but to expand the robotic laser cataract market itself, and continue to demonstrate we are well equipped to do so," said CEO Nick Curtis. "We closed 2025 with continued momentum in ALLY adoption and utilization, reinforcing the durability of our recurring revenue model, with 79% of revenue for both the fourth quarter and the full year coming from recurring sources. During Q4, we expanded the ALLY installed base to approximately 200 systems, representing a 48% increase over the end of 2024, while worldwide volume increased 22% in 2025 compared to 2024. Procedure growth, both in the U.S. and abroad, remained robust and reflects increasing utilization across our growing installed base, providing clear evidence of the compelling value surgeons see in our technology and a clear path for LENSAR to continue growing its recurring revenue base and its overall business."
0 · Reply
HotBaht
HotBaht Mar. 22 at 3:57 PM
$LNSR @SQUEAKSBANDIT You may be right but we have Q4 earnings at the end of the month and it's historically their best quarter. This will be the first earnings call in the last year and I expect we will hear good things about the speed of system placement in 2026 and beyond as they re-commit with dealers and refocus. The $10M was sorely needed but it definitely didn't cover the cost of this long regulatory scrutiny even without considering the associated slowdown in growth. They were negligent not requiring a larger reverse breakup fee. $15M-$30M would have been more typical given the deal size.
2 · Reply
ap20
ap20 Mar. 18 at 7:21 PM
$LNSR Added.
0 · Reply
FiftyEight
FiftyEight Mar. 18 at 1:01 PM
$EONR $BATL $OPEN $FRGT I am looking at $LNSR now. $12 stock on sale for $7 after buyout fell through!
0 · Reply
FiftyEight
FiftyEight Mar. 18 at 12:38 PM
$LNSR cheap entry point
0 · Reply
SQUEAKSBANDIT
SQUEAKSBANDIT Mar. 17 at 5:08 PM
$LNSR idk what kinda value remains even with the 10MM but these broken deal plays can take 6-12mo or more to bottom out
0 · Reply
notreload_ai
notreload_ai Mar. 17 at 11:31 AM
$LNSR and $ALC have mutually terminated their merger after the Federal Trade Commission threatened to block the deal. https://notreload.xyz/lensar-terminates-alcon-merger-after-ftc-block-stock-drops/
0 · Reply
BioGem
BioGem Mar. 17 at 7:14 AM
$LNSR I would short anything above $8, many lethal negatives. -Adoption and growth are weak over the years. -Gross margin is terribly low. -Operating expenses are swelling = heavy losses and are far away from any breakeven. -Cash is critically low. -Raised expensive debt = high interest with worse net losses, the spiral toward financial stress is accelerating. -Preferred shares and warrants vested are quite dilutive.
1 · Reply